Literature DB >> 12648469

The ErbB receptors and their role in cancer progression.

Thomas Holbro1, Gianluca Civenni, Nancy E Hynes.   

Abstract

The involvement of the ErbB receptor tyrosine kinases in human cancer, as well as their essential role in a variety of physiological events during normal development, have motivated the interest in this receptor family. Approaches taken to block the activity of ErbB receptors in cancer cells have not only proven that they drive in vitro tumor cell proliferation, but have also become clinically relevant for targeting tumors with deregulated ErbB signaling. The mechanisms and downstream effectors through which the ErbB receptors influence processes linked to malignant development, including proliferation, cell survival, angiogenesis, migration, and invasion, are, however, only now becoming apparent. Our particular emphasis in this review will be on how ErbB receptors, in particular ErbB1 and ErbB2, contribute to processes linked to cancer progression. Importantly, in keeping with the emerging theme that ErbB receptors do not function in isolation, we will focus on receptor cooperativity, i.e., ErbB1 cooperates with other classes of receptors, and the ligand-less ErbB2 functions as a heterodimer with other ErbBs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648469     DOI: 10.1016/s0014-4827(02)00099-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  207 in total

Review 1.  Epidermal growth factor receptor mediates injury in rapidly progressive glomerular disease.

Authors:  Sabine Brandt; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-03-24       Impact factor: 2.370

Review 2.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

3.  Specific posttranslational modification regulates early events in mammary carcinoma formation.

Authors:  Hua-Bei Guo; Heather Johnson; Matthew Randolph; Tamas Nagy; Ryan Blalock; Michael Pierce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Authors:  Meghan M Morrison; Katherine Hutchinson; Michelle M Williams; Jamie C Stanford; Justin M Balko; Christian Young; Maria G Kuba; Violeta Sánchez; Andrew J Williams; Donna J Hicks; Carlos L Arteaga; Aleix Prat; Charles M Perou; H Shelton Earp; Suleiman Massarweh; Rebecca S Cook
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

5.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

6.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Single-molecule analysis of epidermal growth factor signaling that leads to ultrasensitive calcium response.

Authors:  Takeshi Uyemura; Hiroaki Takagi; Toshio Yanagida; Yasushi Sako
Journal:  Biophys J       Date:  2005-03-04       Impact factor: 4.033

8.  PI3K and Erk MAPK mediate ErbB signaling in Xenopus gastrulation.

Authors:  Shuyi Nie; Chenbei Chang
Journal:  Mech Dev       Date:  2007-07-19       Impact factor: 1.882

9.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 10.  Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.

Authors:  Elizabeth A Musgrove; Elizabeth A Davison; Christopher J Ormandy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.